| SESSION 10: NEW DEVELOPMENTS IN CONTRACEPTION,
SEXUAL AND REPRODUCTIVE HEALTH |
 |
| nr. |
title |
1st
author |
abstract |
| P181 |
Enhancement of the specific advantages of the drospirenone-containing pill by long-cycle contraception
|
A.O. Mueck (Germany) |
abstract |
| P182 |
Is Evra, a transdermal, once-weekly, combined contraceptive patch cost-effective compared to
combined oral contraceptives?
|
F.A. Sonnenberg (USA) |
abstract |
| P183 |
Effect of oral contraceptives on endogenous estradiol metabolism
|
A.O. Mueck (Germany) |
abstract |
| P184 |
New FDA approved latex-free contraceptive device: FemCap
|
A. Shihata (USA) |
abstract |
| P185 |
New combined oral contraceptive containing drospirenone and changes in body weight during six
usage cycles
|
D. Driák (Czech Republic) |
abstract |
| P186 |
First pill teach
|
K. Guthrie (UK) |
abstract |
| P187 |
An assessment of the use of Implanon® in Luton
|
A. Agrawal (UK) |
abstract |
| P188 |
Can there be a genetic background of the primary idiopathic infertility? The leukemia-inhibitory factor
gene mutations in the population of infertile women
|
Z. Rokyta (Czech Republic) |
abstract |
| P189 |
Using menstrual data to time the administration of mifepristone as once-a-month contraceptive pill
|
N. Narvekar (UK) |
abstract |
| P190 |
Determinants of use of the monthly contraceptive ring – a study of the Basque Society of
Contraception
|
R. Lertxundi (Spain) |
abstract |
| P191 |
NuvaRing does not interact with oral antibiotics
|
P. Dogterom (The Netherlands) |
abstract |
| P192 |
NuvaRing does not affect bone mineral density in pre-menopausal women
|
R. Massai (Chile) |
abstract |
| P193 |
Holistic sexual health care in recipients of high dose chemotherapy or chemo-radiotherapy and bone
marrow transplantation for haematological malignancy presenting with sexual dysfunction
|
R. Chatterjee (UK) |
abstract |
| P194 |
Office hysteroscopic sterilization using the Essure micro-insert device
|
M. Martinho (Portugal) |
abstract |
| P195 |
Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen and glucocorticoid
receptor
|
N. Narvekar (UK) |
abstract |
| P196 |
Does use of the combined oral contraceptive pills cause changes in nasal physiology in young women?
|
C.M. Philpott (UK) |
abstract |
| P197 |
Uterine manipulation with plastic suction curette at combined abortion and sterilization
|
A.K. Banerjee (UK) |
abstract |
| P198 |
Prevention of errors when using oral contraceptives
|
M. Havlín (Czech Republic) |
abstract |
| P199 |
Cycle control with NuvaRing is superior to a 30 mg ethinylestradiol oral contraceptive
|
K. Oddsson (Iceland) |
abstract |
|
|
|
|